Cantor Fitzgerald last night initiated coverage of Korro Bio (KRRO) with an Overweight rating and $74 price target Korro is a leading developer of RNA editing oligonucleotide therapeutics, the analyst tells investors in a research note. The firm says KRRO-110 could constitute the best approach for Alpha-1 antitrypsin deficiency, an “increasingly competitive but seemingly large indication.” Korro’s next clinical program could be in phenylketonuria or a similar condition, adds Cantor.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue